Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells <i>In vivo</i> and <i>In vitro</i> Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis

Abstract

These results identify HIF-1alpha as a promising target and provide a rationale for clinical trials of low-dose irinotecan and rapamycin combination toward metastatic colon cancer.